Business Description
![Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd logo](https://static.gurufocus.com/logos/0C00000CM5.png?14)
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : US8816242098
Share Class Description:
MEX:TEVA: ADRCompare
Compare
Traded in other countries / regions
TEVA.IsraelTEVA.USA0LER.UKTEV.GermanyTEVA.MexicoT1EV34.BrazilTEVA.Austria IPO Date
2011-02-23Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 2.74 | |||||
Debt-to-EBITDA | 15.26 | |||||
Interest Coverage | 3.26 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.21 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.4 | |||||
3-Year EPS without NRI Growth Rate | -0.1 | |||||
3-Year FCF Growth Rate | 8.9 | |||||
3-Year Book Growth Rate | -9.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.05 | |||||
Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 11.89 | |||||
9-Day RSI | 34.62 | |||||
14-Day RSI | 50.07 | |||||
6-1 Month Momentum % | 63.97 | |||||
12-1 Month Momentum % | 119.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.89 | |||||
Quick Ratio | 0.61 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 180.92 | |||||
Days Sales Outstanding | 78.57 | |||||
Days Payable | 109.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 7.32 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.95 | |||||
Operating Margin % | 20.79 | |||||
Net Margin % | -3.08 | |||||
FCF Margin % | 5.54 | |||||
ROE % | -6.73 | |||||
ROA % | -1.15 | |||||
ROIC % | 8.37 | |||||
ROC (Joel Greenblatt) % | 3.05 | |||||
ROCE % | 0.6 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 5.43 | |||||
PE Ratio without NRI | 6.04 | |||||
PS Ratio | 1.11 | |||||
PB Ratio | 2.47 | |||||
Price-to-Free-Cash-Flow | 20.25 | |||||
Price-to-Operating-Cash-Flow | 12.78 | |||||
EV-to-EBIT | 189.21 | |||||
EV-to-Forward-EBIT | 41.16 | |||||
EV-to-EBITDA | 26.92 | |||||
EV-to-Forward-EBITDA | 18.36 | |||||
EV-to-Revenue | 2.2 | |||||
EV-to-Forward-Revenue | 2.2 | |||||
EV-to-FCF | 39.77 | |||||
Price-to-Projected-FCF | 1.4 | |||||
Price-to-Median-PS-Value | 1.47 | |||||
Earnings Yield (Greenblatt) % | 0.53 | |||||
FCF Yield % | 4.86 | |||||
Forward Rate of Return (Yacktman) % | 16.83 |